Drug Database
Back to search

Belgium· BE-AMP-SAM664011-00

Andembry 200 mg

A garadacimab product containing garadacimab, registered in Belgium by CSL Behring. The same ATC class is registered in 11 of our 19 countries.

ATC B06AC07

Checked against FAMHP / AFMPS (Belgium) on

Informational only — not a medical device.

SOURCE REGISTER · BEFAMHP / AFMPS (Belgium)normalisedAndembry 200 mgATCB06AC07REGISTER NO.BE-AMP-SAM664011-00PACKS LISTED0CHECKEDSeptember 26, 2026
Compare price across countriesPer daily dose · free accountAsk the assistant about garadacimabAnswers with sources · free accountCheck interactionsSeverity free · mechanism on Growth

Where it is registered

Garadacimab is registered in 11 of 19 countries.

Countries holding a registration under ATC B06AC07 (garadacimab), each read from that country’s own register.

  • This record: Belgium, from FAMHP / AFMPS (Belgium)
  • 7 of them publish a price we can compare per daily dose
Search garadacimab products by name

Garadacimab · ATC B06AC07

11 / 19 countries

  • Belgiumprice
  • Czechiaprice
  • Denmark
  • Finlandprice
  • Icelandprice
  • Ireland
  • Netherlands
  • Norwayprice
  • Switzerlandprice
  • United Kingdom
  • United Statesprice
Blue: a registration under this ATC code. The ringed marker is this record’s country. Markets marked price publish a price we can compare per daily dose.

The record

At a glance

FAMHP / AFMPS (Belgium)
Active substance
Garadacimab
Manufacturer
CSL Behring
Country
Belgium (BE)
ATC code
B06AC07
ATC class
Garadacimab
Defined daily dose
6.7 mg, P
Reimbursed
Not published by this register
Source register
FAMHP / AFMPS (Belgium)
Last checked
September 26, 2026

Packs & prices · 0

No packs listed by the register for this record.

Regulatory notes

No shortage, Orange Book or US label notes for this record.

Same medicine, other countries

Garadacimab in 12 other countries

What each register calls a product with the same active substance — salts and hydrates count as the same.

All garadacimab products

Authorised across Europe · EMA

The same active substance is authorised in 3 EEA countries. Names it is sold under:

  • Iceland · Andembry
  • Liechtenstein · Andembry
  • Norway · Andembry

Source: European Medicines Agency, Article 57 product data.

Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of FAMHP / AFMPS (Belgium). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.

For developers

The same record over the API, and the raw payload
GET /v1/drugs/91d27eb8-1bbf-44e6-b1ca-384003502677
GET /v1/drugs/91d27eb8-1bbf-44e6-b1ca-384003502677?format=fhir

Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.

{
  "form": "Solution for injection in pre-filled syringe",
  "source": "afmps",
  "status": "AUTHORIZED",
  "name_en": "Andembry 200 mg",
  "name_fr": "Andembry 200 mg",
  "name_nl": "Andembry 200 mg",
  "amp_code": "SAM664011-00",
  "strengths": [
    "200.0000",
    "200.0000",
    "19.3000",
    "19.3000",
    "0.2400"
  ],
  "pack_count": 2,
  "substances": [
    "Garadacimab",
    "Proline",
    "Polysorbate 80"
  ],
  "medicine_type": "ALLOPATHIC",
  "atc_description": "Garadacimab",
  "authorisation_numbers": [
    "EU/1/24/1885/002",
    "EU/1/24/1885/001"
  ]
}
API referenceMCP serverPlans

See everything about garadacimab.

This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.

Try it freeOpen in the console